Azora Therapeutics, Inc. Common Stock
AZR
5 hedge funds and large institutions have $56K invested in Azora Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.29% more ownership
Funds ownership: 0% → 0.29% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$56K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.08K |
| 3 |
Morgan Stanley
New York
|
+$2.08K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$2.08K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.08K |
Top Sellers
AZR Hedge Fund Activity: Q3 2018 in Review
5 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Azora Therapeutics, Inc. Common Stock (AZR) for Q3 2018, worth a combined $56K.
Buyers outnumbered sellers: 5 funds opened new AZR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $56K.
- 5 institutional investors held Azora Therapeutics, Inc. Common Stock (AZR) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $56K of Azora Therapeutics, Inc. Common Stock stock for Q3 2018.
- 5 funds opened new Azora Therapeutics, Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +5 holders.
- The largest Azora Therapeutics, Inc. Common Stock buyer in Q3 2018 was Millennium Management, an estimated $56K added.
Based on aggregated 13F filings for Q3 2018.